DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rnh27x/antibodydrug) has announced the addition of the "Global Antibody-Drug Conjugates Market 2014" report to their offering.
The ADC pipeline analysis describes preclinical, non-clinical and clinical ADC projects and R&D programs. It evaluates the ADC targets in relation to drug and linker systems, and also investigates the clinical success and reasons for failures of antibody-drug conjugates.
The stakeholder analysis compares companies with their peers in the respective group of development, technology and manufacturing companies and further categorizes them within the respective group to find out their competitive situation.
The analysis pays special attention to the importance of target selection, to emerging trends of new targeting moieties beyond full-length, canonical antibodies, to the expansion of the use of ADCs in non-cancer indications, to the opportunities arising from new site-specific and from polymer/nanoparticel-based conjugation systems and the most promising new payloads for ADCs.
Critical issues of ADCs, such as therapeutic window, druggable targets, manufacturing and financing are addressed and opportunities outlined.
Who will benefit from the report:
- Investors
- Business developers
- Licensing managers
- Technology officers
- R&D Management
- Business & Competitive Intelligence Analysts
- Scientific Analysts
- R&D Planning
- Portfolio Managers
What will you find in the report?
- Company profiles of ADC stakeholders
- ADC drug profiles
- ADC business agreements
- ADC pipeline description and analysis
- Clinical attrition rate of ADCs and reasons for failure
- ADC target description and analysis
- Current and future drugs, linkers and conjugation systems
- Industry preferences for drugs and linkers
- Alternative targeting moieties
- New uses of ADCs and immunoconjugates
- CMOs for manufacturing of ADCs
- Competitors in development, technology or manufacturing
- Commercial value of ADC products and technologies
Key Topics Covered:
- Executive Summary
- Introduction and Overview of the Report
- Antibody-Drug Conjugates: Pipeline Description and Analysis
- Stakeholders in Antibody-Drug Conjugates and Immunoconjugates
- ADC Technologies
- Business with Antibody-Drug Conjugates
- ADC & Immunoconjugate Company Profiles
- References
For more information visit http://www.researchandmarkets.com/research/rnh27x/antibodydrug
